Texas A&M University Health Sciences Center, College of Medicine, Houston, TX, United States.
Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Br J Radiol. 2022 Sep 1;95(1138):20211350. doi: 10.1259/bjr.20211350. Epub 2022 Mar 4.
Oligometastatic disease represents a clinically discrete intermediate stage of cancer progression and is an expanding area of research. While surgical metastatectomy has been recognized for decades as an effective treatment option in select patients, options for metastasis-directed therapy have broadened in scope with advancements in the armamentarium of non- and minimally invasive modalities. Recent preclinical studies investigating the immunology surrounding liver metastases demonstrate treatment resistance to immunotherapy in affected patients and show how locoregional therapy has the ability to overcome this resistance. In this paper, we review advancements in our understanding of oligometastatic disease, metastasis-directed therapy, effect of liver metastasis on response to immunotherapy, and the burgeoning role of image-guided interventions in complementing cancer immunotherapy at the exciting crossroads of interventional oncology and immuno-oncology.
寡转移疾病代表癌症进展的一个临床明显的中间阶段,是一个不断发展的研究领域。虽然几十年来,手术转移切除术已被公认为是某些患者的有效治疗选择,但随着非侵入性和微创治疗手段的发展,转移灶定向治疗的选择范围已经扩大。最近的研究探讨了围绕肝转移的免疫学问题,结果显示,受影响的患者对免疫治疗有治疗抵抗性,并且显示了局部治疗有克服这种抵抗性的能力。在本文中,我们回顾了对寡转移疾病、转移灶定向治疗、肝转移对免疫治疗反应的影响以及图像引导介入在补充癌症免疫治疗方面的作用的认识进展,这些进展在介入肿瘤学和免疫肿瘤学的令人兴奋的交汇点上发挥了重要作用。